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Background
The Timothy syndrome (TS) mutations G402S and G406R
abolish inactivation of CaV1.2 and cause multiorgan dys-
function and lethal arrhythmias.
Methods
In order to gain insights into the consequences of the
G402S mutation on structure and function of the channel,
we systematically mutated the corresponding G432 and
the homologous S6 positions of the other three domains
of the rabbit channel and applied homology modeling.
Results
Homology modeling revealed that G432 forms part of a
highly conserved structure motif (G/A/G/A) of small resi-
dues in homologous positions of all four domains (G432
(IS6), A780 (IIS6), G1193 (IIIS6), A1503 (IVS6)). In con-
trast, corresponding mutations in domains II, III and IV
induced parallel shifts of activation and inactivation curves
indicating a preserved coupling between both processes.
Disruption between coupling of activation and inactivation
was specific for mutations of G432 in domain I. Mutations
of G432 removed inactivation irrespective of the changes
in activation. In all four domains residues G/A/G/A are in
close contact with larger bulky amino acids from neigh-
boring S6 helices.
Conclusions
These interactions apparently provide adhesion points
thereby tightly sealing the activation gate of CaV1.2 in the
closed state. Such a structural hypothesis is supported by
changes in activation gating induced by mutations of the
G/A/G/A residues.
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